ProteLight Pharma Completed B Round Capital Raising of RMB 133 million
2018-11-21
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. recently completed the Round B fund-raising of total RMB 133 million yuan, led by a well-known domestic VC firm with outstanding reputation focusing in the field of biological medicine, and jointly invested by local enterprises in Jiangyin. The financing capital of this round is mainly used for the research and development of antimicrobial peptide innovative drugs, the application of clinical approval, clinical trials and related costs of product manufacture. The success of this round of financing will speed up the development of innovative drugs and explore the research depth of antimicrobial peptides. Meanwhile, it will help to expand the influence of the company, market competitiveness and industry scale in the field of antimicrobial peptides.
The antimicrobial peptide PL-5 spray project has now entered the Phase II clinical trial. The antimicrobial peptide PL-5 spray project was selected into the national“12th Five-Year Plan” and “13th Five-Year Plan”Mega-Projects for Innovative Drugs of China.
